37 results about "Arthritis- rheumatoid arthritis" patented technology

The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-CD6 monoclonal antibody for the diagnosis and treatment of Autoimmune Diseases, particularly the Rheumatoid Arthritis.

The invention relates to Gypensapogenin B for treating immune inflammation and preparing a medicament for treating rheumatoid arthritis. By using terfenadine and diclofenac sodium as contrasts, the Gypensapogenin B has definite treatment effect. The application of the Gypensapogenin B in preparation of the medicament for treating rheumatoid arthritis is disclosed for the first time, the skeleton type is a brand-new skeleton type, the Gypensapogenin B has unexpected strong inhibiting activity on the rheumatoid arthritis, the probability of giving any revelation by other compounds does not exit, and the Gypensapogenin B has predominant substantial characteristics and obviously has a remarkable progress in prevention and treatment of the rheumatoid arthritis.

The invention discloses Chukrasone A used for treating immunity inflammation. When seldane and diclofenac sodium are used as control samples, curative effect of Chukrasone A is clear in preparation of medicines used for treating rheumatoid arthritis. The applications of Chukrasone A in preparation of medicines used for treating rheumatoid arthritis is discloses for the first time. The molecular skeleton is novel, so that the inhibitory activity on rheumatoid arthritis is surprisingly strong, and it is impossible to estimate the inhibitory activity according to the inhibitory activities of other compounds. Chukrasone A possesses outstanding substantiality, and the applications of Chukrasone A in prevention and cure of rheumatoid arthritis possess significant advantages.

The invention discloses an antigenic composition which comprises a polypeptide I and a polypeptide II, wherein the molar ratio of the polypeptide I to the sum of the polypeptide I and the polypeptide II is 0-1. An annular polypeptide is generated in a mode of forming a disulfide bond from two nonadjacent cysteine side chain hydrosulphonyls on a sequence. The polypeptide not only can be combined with a rheumatoid arthritis autoimmune antibody, but also can simultaneously have high affinity for HLA-DR. Through experimental verification, the specificity of the polypeptide combined with the rheumatoid arthritis autoimmune antibody is larger than 95 percent, and the detection sensitivity for the rheumatoid arthritis autoimmune antibody is larger than 75 percent. Compared with like products sold on the market, the sensitivity of the composition is markedly improved, thereby being more beneficial to externally detecting the rheumatoid arthritis autoimmune antibody.

Provided are an inhibitor, a prophylactic, and a therapeutic agent for rheumatoid arthritis that have no side effects and that can correct immune abnormality associated with rheumatoid arthritis. The inhibitor, the prophylactic, and the agent for rheumatoid arthritis contain a Euglena-derived material as an active ingredient. The inhibitor, the prophylactic and the agent are used as an antirheumatic drug for controlling the activity of rheumatoid arthritis by alleviating immune abnormality associated with rheumatoid arthritis. The inhibitor, the prophylactic, and the agent are also used for a living individual who has not been definitively diagnosed with rheumatoid arthritis. The inhibitor, the prophylactic, and the agent are continuously administered to the living individual from any point before definitive diagnosis of rheumatoid arthritis to any point after the definitive diagnosis. The Euglena-derived material is at least one material selected from the group including Euglena algae, paramylon derived from the Euglena, water-soluble amorphous paramylon prepared by treating the paramylon with alkali and neutralizing the treated paramylon, and emulsion paramylon prepared by ejecting a solution of the paramylon from a narrow bore nozzle at a very high pressure to cause the solution to collide with a collision surface.

The present invention provides a method of determining the rheumatoid arthritis status of an individual to be tested, or the progression of rheumatoid arthritis, or an appropriate therapy for an individual suffering from rheumatoid arthritis, the method comprising the steps of: (a ) determining the level of tenascin C in a sample from said individual to be tested; and (b) comparing the level of tenascin C determined in step (a) to one or more reference values. Preferably the rheumatoid arthritis referred to is erosive rheumatoid arthritis. Figure 5 is attached when published.

The invention provides an application of a traditional Chinese medicine huanglian jiedu decoction (comprising the Chinese medicine components of 9g of coptis chinensis, 6g of scutellaria baicalensis, 6g of golden cypress and 9g of gardenia) in preparing a medicament for preventing and treating rheumatoid arthritis. When being used for animal pharmacodynamic test, the huanglian jiedu decoction is proved to have the functions of restraining the clinical pothogenesy of CIA (Collagen-Induced Arthritis), obviously restraining the severity and the morbidity of the CIA and having obvious protection function to the CIA. The huanglian jiedu decoction can reduce the contents of TNF-alpha, IL-17 and IFN-gamma in splenocyte supernatant and restrain the secretion of proinflammatory cytokine, i.e. TNF-alpha, IFN-gamma and IL-17, thereby playing a protecting role for the CIA disease. The invention provides a new traditional Chinese medicine for clinically treating rheumatoid arthritis, which can overcome the toxic and side effects of pharmaceutical chemicals, thereby bringing confidence for treating and achieving higher clinical application value.

The invention develops a simplified method for the in-vitro isolation and expansion of umbilical mesenchymal stem cells (MSCs) and confirms that the MSCs obtained by the method have the effects of immunoregulation and inflammation inhibition in the treatment of rheumatoid arthritis.